Annals of Indian Psychiatry

REVIEW ARTICLE
Year
: 2017  |  Volume : 1  |  Issue : 1  |  Page : 8--10

Pimavanserin – drug review


Nithya Gogtay 
 Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Nithya Gogtay
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
India

Pimavanserin is a drug with a novel mechanism of action that has recently received approval management of patients with Parkinson's disease psychoses [PDP]. It is a 5HT2A inverse agonist that has been shown in a randomized controlled trial to be superior to placebo and also reasonably safe and effective. It significantly reduces positive symptoms seen in Parkinson's disease patients with psychosis with no evident impairment of motor function. It offers hope for patients and caregivers with this otherwise distressing and difficult to manage condition and has also paved the way for the use of 5HT2A inverse agonists in this condition.


How to cite this article:
Gogtay N. Pimavanserin – drug review.Ann Indian Psychiatry 2017;1:8-10


How to cite this URL:
Gogtay N. Pimavanserin – drug review. Ann Indian Psychiatry [serial online] 2017 [cited 2019 Jun 27 ];1:8-10
Available from: http://www.anip.co.in/article.asp?issn=2588-8358;year=2017;volume=1;issue=1;spage=8;epage=10;aulast=Gogtay;type=0